A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in Metastatic Uveal Melanoma.
|II||Open||University of Liverpool||32|
0151 794 8935
To find out more information about a hospital within your area click on the pin.
Sorry there are currently no job vacancies
Some useful downloads: